Last reviewed · How we verify

Shanghai Zerun Biotechnology Co.,Ltd — Portfolio Competitive Intelligence Brief

Shanghai Zerun Biotechnology Co.,Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
HPV-16/18 vaccine HPV-16/18 vaccine phase 3 Prophylactic vaccine HPV-16 and HPV-18 L1 capsid proteins Oncology / Immunology
Zerun HPV-9 Zerun HPV-9 phase 3 vaccine Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 2 shared drug classes
  2. Murdoch Childrens Research Institute · 2 shared drug classes
  3. Aeras · 1 shared drug class
  4. Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
  5. Alba Maria Ropero · 1 shared drug class
  6. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  7. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
  8. Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Zerun Biotechnology Co.,Ltd:

Cite this brief

Drug Landscape (2026). Shanghai Zerun Biotechnology Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-zerun-biotechnology-co-ltd. Accessed 2026-05-16.

Related